Tech Company Financing Transactions
WhiteLab Genomics Funding Round
AXA Venture Partners, Blast.Club and Debiopharm Diagnostics participated in a $26 million Series B venture round for WhiteLab Genomics. This VC investment round was announced on 10/6/2026.
Transaction Overview
Company Name
Announced On
10/6/2026
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its in vivo validation programs across viral and non-viral delivery technologies and programmable payloads, while supporting commercial expansion across North America, Europe, and Asia.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4 rue Pierre Fontaine
Evry, 91000
France
Evry, 91000
France
Phone
Undisclosed
Website
Email Address
Overview
We are specialised in AI solutions for advanced therapies such as gene and cell therapies. Our team includes world-class data scientists specialized in AI and machine learning, computational biologists, molecular biologists and genomic medicine scientists.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Bourgo
Chief Scientific Officer
Julien Cottineau
Browse more venture capital transactions:
Prev: 10/6/2026: Sante Technologies venture capital transaction
Next: 10/6/2026: Nettle venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs